<DOC>
	<DOC>NCT00894114</DOC>
	<brief_summary>This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.</brief_summary>
	<brief_title>A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject was previously enrolled in Merck HIV Vaccine study V520 Protocol 007 or 012, and received the complete 3dose regimen during participation Subject is in good general health Subject is not infected with HIV Subject agrees not to donate blood during the first 52 weeks of the study Subject agrees not to donate sperm during the first 12 weeks of the study Subject who is of reproductive potential agrees to use an acceptable method of birth control through Week 12 of the study Subject has been administered immune globulin or blood product 3 months prior to receiving study vaccination Subject has been vaccinated with a live virus vaccine in the past 30 days Subject has been vaccinated with an inactivated vaccine in the past 14 days Subject has an active medical disease Subject is taking daily required prescription drugs Female subject is pregnant, breastfeeding or expecting to conceive Subject is positive for HIV Subject has used injection drug within the past year Subject has a sexual partner that is infected with HIV Subject has a sexual partner that is an active injection drug user Subject has been treated for or diagnosed with a new sexually transmitted disease in the past 6 months Subject engaged in unprotected intercourse with more than 2 persons in the previous 6 months Subject engaged in protected intercourse with more than 4 persons in the previous 6 months Subject has previously participated in an HIV vaccine clinical trial (other than Merck V520 Protocols 007 and 012) Subject weighs less than 110 lbs. Subject has a recent history of alcohol abuse Subject intends to donate blood in the first 52 weeks of the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>